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Renal toxicity commonly occurs after admin-
istration of xenobiotics and a variety of phar-
maceutical agents. The process is typically
initiated by a toxic injury to tubular epithelial
cells in various nephron segments or by
injury to speciﬁc cell types in the glomerulus.
The initial injury is often followed by cellular
proliferation and repair that attempts to
restore normal renal function (Toback 1992).
Changes in the expression of mRNA speciﬁ-
cally expressed in the injured kidney cells are
some of the earliest events that accompany
renal injury. This is accompanied by changes
in the expression of other genes that con-
tribute either to cellular repair or recovery of
renal function or in those that mediate ﬁbro-
sis and further pathology of the kidney
(Matejka 1998; Norman et al. 1988;
Safirstein et al. 1990). For example, eleva-
tions in the expression of heme oxygenase I
(HO-1), kidney injury molecule-1 (KIM-1),
clusterin, thymosin beta 4, osteopontin, and
several growth factors have been reported in
various models of renal injury (Hammerman
1998a, 1998b; Huang et al. 2001; Ichimura
et al. 1998; Yoshida et al. 2002).
Recent application of microarray-based
gene profiling has provided some unique
insights into compound-specific and
toxicity-related gene expression changes in
the liver (Hamadeh et al. 2002a, 2002b;
Waring et al. 2001a, 2001b), and several
laboratories have applied similar techniques
to identify gene expression changes related
to nephrotoxicity (Huang et al. 2001;
Nagasawa et al. 2001; Yoshida et al. 2002). 
This study, conducted as a consortium
collaboration with the International Life
Sciences Institute (ILSI) Health and
Environmental Sciences Institute (HESI)
(Kramer et al. 2004; Pennie et al. 2004),
compares kidney gene expression profiles
induced by cisplatin and gentamicin, com-
pounds that injure the proximal tubule,
and puromycin, which produces protein-
uria by selectively damaging podocytes, a
key component of the glomerular ﬁltration
barrier to plasma proteins. Conventional
clinical chemistry and histopathological or
ultrastructural findings confirmed the
induction of tubular or glomerular injury in
these studies. Through comparison of the
expression profiles derived from kidneys
exposed to these three nephrotoxicants at
multiple doses and time points (associated
with varying types and severity of toxicity),
we hypothesized that we could identify pat-
terns of gene expression that reflect differ-
ent types of nephrotoxicity. An important
outcome is the identification of potential
gene-based markers of nephrotoxicity and
evidence that one can detect region-speciﬁc
renal toxicity using microarray technology.
Additional functional genomics studies may
afford the opportunity to validate the pro-
posed novel gene-based markers of nephro-
toxicity, which in part may improve current
sensitivity to assessing xenobiotic-induced
nephrotoxicity. 
Materials and Methods
General
This study was conducted in accordance
with Good Laboratory Practices. All
animals were handled and treated in accor-
dance to the NIH Guide for the Care
and Use of Laboratory Animals (NIH
1999). Experiments were performed on
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This study, designed and conducted as part of the International Life Sciences Institute working group
on the Application of Genomics and Proteomics, examined the changes in the expression proﬁle of
genes associated with the administration of three different nephrotoxicants—cisplatin, gentamicin,
and puromycin—to assess the usefulness of microarrays in the understanding of  mechanism(s) of
nephrotoxicity. Male Sprague-Dawley rats were treated with daily doses of puromycin (5–20
mg/kg/day for 21 days), gentamicin (2–240 mg/kg/day for 7 days), or a single dose of cisplatin
(0.1–5 mg/kg). Groups of rats were sacriﬁced at various times after administration of these com-
pounds for standard clinical chemistry, urine analysis, and histological evaluation of the kidney. RNA
was extracted from the kidney for microarray analysis. Principal component analysis and gene expres-
sion–based clustering of compound effects conﬁrmed sample separation based on dose, time, and
degree of renal toxicity. In addition, analysis of the proﬁle components revealed some novel changes
in the expression of genes that appeared to be associated with injury in specific portions of the
nephron and reflected the mechanism of action of these various nephrotoxicants. For example,
although puromycin is thought to speciﬁcally promote injury of the podocytes in the glomerulus, the
changes in gene expression after chronic exposure of this compound suggested a pattern similar to the
known proximal tubular nephrotoxicants cisplatin and gentamicin; this prediction was conﬁrmed his-
tologically. We conclude that renal gene expression proﬁling coupled with analysis of classical end
points affords promising opportunities to reveal potential new mechanistic markers of renal toxicity.
Key words: biomarkers, cisplatin, gentamicin, microarrays, nephrotoxicity, proximal tubule,
puromycin, toxicogenomics. Environ Health Perspect 112:465–479 (2004). doi:10.1289/txg.6683
available via http://dx.doi.org/ [Online 15 January 2004]approximately 8- to 9-week-old male
(approximately 250–300 g) Sprague-
Dawley rats Crl:CD (SD)IGS BR VAF+
(abbreviated SD) purchased from Charles
River Breeding Laboratories (Raleigh, NC).
Food [Purina Rodent Chow no. 5002
(Purina Milling Inc., St. Louis, MO), or
Certified Rodent Diet 18% no. 5LG3,
(PMI Feeds, Richmond, IN)], except for
study-deﬁned fasting procedures, and water
were available ad libitum. 
Test Article and Treatment
Cisplatin (CAS no. 15663-27-1; lot
059H3657), gentamicin sulfate (CAS no.
1405410; lot 50K0924), and puromycin
dihydrochloride hydrate (CAS no. 58-58-2;
Lot 080K4031) were purchased from
Sigma Chemical Company (St. Louis,
MO). Doses were selected based on previ-
ous reports that documented histopatholog-
ical changes in the kidney by the 7-day time
point or later. The rats received a single ip
injection of vehicle (0.9% NaCl solution)
or cisplatin at a dose of 0.3, 1, or 5 mg/kg
(20 per group). Cisplatin- and vehicle-
treated rats were sacriﬁced by inhalation of
carbon dioxide 4, 24, 48, and 144 hr after
injection of vehicle or cisplatin. This por-
tion of the study was conducted at Pfizer
Inc (Groton, CT).
Gentamicin was dissolved in a sterile
0.9% (w/v) NaCl solution and the animals
were treated with daily ip injections of
vehicle or gentamicin at doses of 2, 20, 80
or 240 mg/kg/day for up to 7 days. A
group of rats (three to ﬁve per group) were
sacriﬁced at 4, 24, 48, and 144 hr after the
initial administration of gentamicin. This
portion of the study was conducted at
Novartis Pharmaceuticals (East Hanover,
NJ) and the Medical College of Wisconsin
(Madison, WI). 
Puromycin was dissolved in sterile
0.9% (w/v) NaCl solution. The rats
received daily ip injections of vehicle or
puromycin at doses of 5 or 20 mg/kg/day
for up to 21 days. Puromycin-treated and
time-matched vehicle control animals were
sacriﬁced at 4, 24, 48, and 144 hr, and 21
days after the first exposure to the com-
pound. This portion of the study was co-
ordinated by staff from the National
Institute of Environmental Health Sciences
(NIEHS; Research Triangle Park, NC).
Urine Collection
Animals were placed in standard metabolic
cages overnight (approximately 12–14 hr)
prior to necropsy. Food but not water was
removed from the animals during this
time. Urine volumes were recorded and the
urine samples were frozen and stored at
–80°C for subsequent analysis. 
Tissue Collection
After CO2 anesthesia, a sample of blood was
collected from the vena cava for standard
clinical chemistry analysis. The kidneys were
collected, weighed, and stored frozen. Half
the kidney and the left lobe of the liver were
placed in 10% neutral buffered formalin for
histology, and the other half was ﬂash-frozen
in liquid nitrogen and stored at –80°C for
Western blot or immunohistochemical
analysis. The right kidney was minced,
transferred to 5 mL RLT with β-mercapto-
ethanol (+ BME) buffer (Qiagen, Valencia,
CA) in a 50-mL centrifuge tube and
homogenized for 60–120 sec. Additional
RLT (+ BME) buffer was added to achieve a
ﬁnal volume of 30 mL, which was divided
into 15-mL aliquots and stored at –80°C
until the RNA was extracted. 
Histology
The tissues were fixed for a maximum of
48 hr and then transferred to 70% ethanol
for up to 10 days before being placed in
paraffin. The tissues were embedded in
parafﬁn blocks, cut into 5-µm sections, and
stained with hematoxylin and eosin
(H&E). Ultrastructural analysis using elec-
tron microscopy was performed on kidney
tissue obtained from animals treated with
gentamicin. In this case the kidney tissue
was fixed with paraformaldehyde rather
than formalin. 
Clinical Chemistry and Urinalysis
At scheduled necropsies, blood (fasted, vena
cava bleeding; approximately 2–3 mL) was
collected into serum separation collection
tubes and allowed to clot. Serum was col-
lected (centrifugation at approximately 4°C,
1,500 × g, 10 min) and stored frozen at –70
to –80°C for routine serum biochemistry
analysis. Albumin, alkaline phosphatase,
alanine amino transferase, aspartate amino
transferase, bilirubin, blood urea nitrogen
(BUN), calcium (Ca2+), chloride, creati-
nine, gamma glutamyltransferase, glucose,
magnesium, phosphate, 5´-nucleotidase,
potassium, sorbitol dehydrogenase, sodium,
total cholesterol, and total protein were
among the parameters measured using a
standard clinical chemistry analyzer.
Urinary creatinine, total protein, glucose,
calcium, sodium, potassium, chloride, mag-
nesium, and phosphorus concentrations
were also analyzed. 
Statistical Analysis
Mean values ± 1 standard error (SE) are
presented for serum biochemistry, urine
chemistry, and organ and body weight meas-
urements. Signiﬁcance of the differences in
mean values were evaluated using either a
one-way analysis of variance followed by a
Duncan’s multiple range post hoc analysis
(more than two groups) or a Student t test
for comparison between two mean values.
RNA Extraction
Homogenized kidney samples (one of two
15-mL samples per animal) were processed
using a Qiagen RNeasy Maxi kit (Qiagen)
according to the manufacturer instructions.
Final RNA product was quantiﬁed from the
ultraviolet absorbance at 260 nm (Beckman
DU520UV/Vis Spectrophotometer;
Beckman Coulter Inc., Fullerton, CA). The
quality of the RNA was evaluated by mea-
suring the 260-/280-nm ratios and con-
firmed by formaldehyde agarose gels or
analysis of the sample on a Bioanalyzer
(Agilent Technologies, Palo Alto, CA).
RNA was deemed of a suitable quality for
microarray analysis if the 260/280 ratio was
between 1.6 and 2.0 and the gel and
Bioanalyzer traces showed no visible degra-
dation products lower than the 18S riboso-
mal band. An equal amount of RNA
extracted from the kidney of all rats in a
treatment group was pooled into single
samples. In select instances RNA from kid-
ney of individual animals was also analyzed
by microarray and/or by RT–PCR. Samples
were stored at –80°C until hybridization. 
cDNA Microarray Manufacturing
Gene expression analysis was conducted on
the same RNA samples using several plat-
forms including Affymetrix (Santa Clara,
CA) and NIEHS custom cDNA microar-
rays. The analysis of samples using the
Affymetrix platform was performed accord-
ing to the manufacturer details (Affymetrix
2003; Lockhart et al. 1996) and is detailed
in the accompanying paper (Thompson
et al. 2004). 
The analysis using the custom cDNA
microarray manufactured at NIEHS is as
follows: Sequence-veriﬁed rat cDNA clones
that covered the 3´ end of the gene and
ranged in size from 500 to 2,000 bp
(Research Genetics, Huntsville, AL) were
printed on glass slides. M13 primers were
used to amplify insert cDNAs from puri-
ﬁed plasmid DNA in a 100-µL polymerase
chain reaction (PCR) reaction mixture. A
sample of the PCR products (10 µL) was
separated on 2% agarose gels to ensure
quality of the amplifications. The remain-
ing PCR products were puriﬁed by ethanol
precipitation, resuspended in ArrayIt buffer
(TeleChem Intl. Inc., Sunnyvale, CA), and
spotted onto poly-L-lysine–coated glass
slides using a modified robotic DNA
arrayer (Beecher Instruments, Bethesda
MD) with TeleChem pins to produce the
NIEHS rat chip containing > 7,000 clones.
A list of clones on this chip is available on
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Group 2003a). Methods were adapted
from DeRisi et al. (1996) and are avail-
able on the NIEHS web site (NIEHS
Microarray Group 2003b)
cDNA Microarray Hybridization
and Analysis
For microarray hybridizations, each total
RNA sample (35–75 µg) was labeled with
Cyanine 3 (Cy3)- or Cyanine 5 (Cy5)-con-
jugated dUTP (Amersham, Piscataway,
NJ) by a reverse transcription reaction
using the reverse transcriptase SuperScript
(Invitrogen, Carlsbad, CA) and the primer
Oligo dT (Amersham). Control samples
were labeled with Cy3, whereas samples
derived from chemically exposed animals
were labeled with Cy5. The fluorescently
labeled cDNAs were mixed and hybridized
simultaneously to the cDNA microarray
chip. Each RNA pair was labeled and
hybridized independently in duplicate or
quadruplicate to a total of two to four
arrays. The cDNA chips were scanned with
an Axon Scanner (Axon Instruments,
Foster City, CA) using independent laser
excitation of the two ﬂuors at 532 and 635
nm wavelengths for the Cy3 and Cy5
labels, respectively. Image analysis, back-
ground subtraction, normalization, and
determination of significant gene changes
were conducted using the ArraySuite, ver-
sion 2.0 extensions of the IPLab image pro-
cessing software package (Scanalytics,
Fairfax, VA) (Chen et al. 1997) as previ-
ously described (Bushel et al. 2001, 2002;
Hamadeh et al. 2002a, 2002b, 2002c). 
Hierarchical cluster analysis was carried
out with the Cluster, version 2.12, and
TreeView, version 1.6, package (Eisen et al.
1998). The cDNA data set is available
from NIEHS (NIEHS Microarray Group
2003c). The complete data set is currently
being submitted to ArrayExpress (EMBL-
European Bioinformatics Institute,
Hinxton, U.K.; http://www.ebi.ac.uk/
arrayexpress) and will be available for pub-
lic download by the second quarter of
2004. Accession numbers referencing this
data set will be available on the HESI web
site (http://hesi.ilsi.org/index.cfm?pubenti-
tyid=120). GeneSpring, version 4.2
(Silicon Genetics, Redwood City, CA),
Cluster, and TreeView software (Eisen et
al. 1998) were used to perform the self-
organizing maps (SOM) procedure and/or
visualize sets of genes constituting the
union of all significant gene changes from
each dose and time point. SOM is a neural
network architecture that categorized simi-
lar trends in the expression pattern of genes
across multiple doses and time points. In
addition, Partek Pro, version 5.02 (Partek
Inc., St. Charles, MO), was used to further
elucidate discriminate gene sets using
principal component analysis (PCA).
Real-Time Quantitative PCR
RNA samples representing single animals
treated with cisplatin or gentamicin were
also used to validate the expression profile
of several genes identified using cDNA
microarray data including osteopontin, inos-
itol polyphospate multikinase, L-arginine
glycine amidinotransferase, prosaposin,
lipocalin, synaptogyrin 2, kallikrein, KIM-1,
and an expressed sequence tag (EST)
(GenBank accession no. AA957270). The
primers for these genes were designed using
Primer Express (Applied Biosystems, Foster
City, CA) and custom made (Bioserve
Biotechnologies, Laurel, MD) except for
renal kallikrein primers and probe that was
purchased from Applied Biosystems assay by
design service. 
Real-time PCR was performed using the
ABI Prism 7700 Sequence Detection System
(Applied Biosystems) according to the man-
ufacturer instructions. Primer and probe
sequences are listed later in this section.
Primer and probe concentrations were opti-
mized such that the ampliﬁcation efﬁciency
of the endogenous reference was similar to
that of the target gene. The endogenous ref-
erence used for samples was actin RNA. For
the cisplatin samples the SYBR Green I
labeling kit (Applied Biosystems) was used
according to the manufacturer instructions
to detect double-stranded DNA generated
during PCR ampliﬁcation. Reverse transcrip-
tion and PCR reactions were performed at
the same time in a 50-µL reaction containing
4 mM magnesium chloride, 0.8 mM of each
dNTP, 100 ng total RNA, 0.4 µM reverse
primer, 0.4 µM forward primer, 0.4 U/µL
RNasin, 0.025 U/µL AmpliTaq Gold DNA
polymerase (Roche, Basel, Switzerland), and
0.25 U/µL MulV reverse transcriptase
(Roche). Amplification reactions were car-
ried out using the following temperature
proﬁle: 48°C, 30 min; 95°C, 10 min; 95°C,
15 sec; 60°C, 1 min) for 40 cycles.
Fluorescence emission was detected for each
PCR cycle and the threshold cycle (CT) val-
ues were determined. The CT value was
defined as the actual PCR cycle when the
ﬂuorescence signal increased above the back-
ground threshold. Induction or repression of
a gene in a treated sample relative to control
was calculated as follows: fold increase/
decrease = 2 – [CT(exposed) – CT(control)].
Values are reported as an average of triplicate
analyses. For the gentamicin samples, reverse
transcription and PCR were carried out in a
25-µL reaction volume using 10 ng total
RNA in triplicate per reaction, 5 nM
forward and reverse primer, and 25 nM
FAM-MGB–labeled probe. Taqman one-
step PCR master mix reagent kit (Applied
Biosystems) was used for all reactions
according to manufacturer’s specifications.
All reactions were carried out using the ABI
Prism 7700 Sequence Detection System
(Applied Biosystems). Transcript levels
were measured using the comparative CT
methods described in User Bulletin No. 2
(Applied Biosystems 1997). 
The following primers, listed in the 5´
to 3´ direction, were used for reverse
transcription-PCR (RT–PCR) verification
of gentamicin-induced gene expression
changes: kallikrein (GenBank accession no.
M19647) forward = GCACCGGCTT
GTCAGTCAA, probe = CCCTCACC
CTGACTAC, reverse = TCGGGTGTG
GTTCCTCATG; prosaposin (GenBank
accession no. NM_013013) forward =
AAGAGCCCAAGCAGTCTGCAT,
probe = CGCCCATGTGCCTC, reverse =
TGTTCCAAATAGATGACCAGCTT
CT; osteopontin (GenBank accession no.
M99252) forward = CCAGCACACAAG
CAGACGTTT, probe = CAGTCGATGT
CCCTGAC, reverse = CAGTCCGTAA
GCCAAGCTATCA; KIM-1 (AF35963)
forward = CGCAGAGAAACCCGAC
TAAG, reverse = CAAAGCTCAGAGAG
CCCATC; glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) (GenBank acces-
sion no. M17701) forward = AGATGG
TGAAGGTCGGTGTC, reverse = ACTG
TGGTCATGAGCCCTTC; cyclophilin B
(GenBank accession no. AF071225) for-
ward = CAAGCCACTGAAGGATGTCA,
reverse = AAAATCAGGCCTGTGG
AATG; Cytb1 (GenBank accession no.
J01435) forward = CGTCACAGCCCA
TGCATTCG, reverse = CTGTTCATCC
TGTTCCAGCTC.
The following primers, listed in the
5´ to 3´ direction, were used for RT–PCR
verification of cisplatin-induced gene
expression changes: Mipmk (GenBank
accession no. NM_134417) forward =
TGCCTGTCCACACTACATACA
GATG, reverse = CGGCATTTAGGAAT
CCGTTCT; L-arginine glycine amidino-
transferase (GenBank accession no.
U07971) forward = CGAGGCGGTGC
ACTACATC, reverse = GCACAGGAAT
TTTGGGAGGAA; lipocalin/EST
(GenBank accession no. NM_130741) for-
ward = GCAGTGGCCTGATGGTTCA,
reverse = GCACAGGAATTTTGGGA
GGAA; synaptogyrin 2 (GenBank acces-
sion no. AI058493) forward = TGCTCG
GCTCCCCACTT, reverse = CTGGAG
ACGGTTGGCACAGT; Prosaposin
(GenBank accession no. M19936) forward
= ACTGCTGCCCGATGCAAT, reverse
= AAGTAGGCGACTTCTGCAAGCT.
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Samples of renal tissue were homogenized
in 10 mM potassium homogenization
buffer containing 250 mM sucrose,
1m MEDTA, and 0.1 mM phenylmethyl-
sulfonyl fluoride, adjusted to pH 7.6.
Homogenates were centrifuged at 3,000 ×
g for 5 min and 9,000 × g for 15 min. The
renal homogenates (50 µg) were separated
by electrophoresis on an 8% sodium dode-
cyl sulfate–polyacrylamide gel elec-
trophoresis gel and transferred to a
nitrocellulose membrane in a transfer
buffer (25 mM Tris, 192 mM glycine, and
20% methanol) at 100 volts at 4°C for
2 hr. The membranes were blocked in a
TBST-20 buffer (10 mM Tris, 150 mM
NaCl, and 10% nonfat dry milk) overnight
and incubated with a 1:1000 dilution of
primary antibodies raised against heme
oxygenase 1 (StressGen, Vancover,
Canada) or KIM-1 (kindly provided by
J. Bonventre, Massachusetts General
Hospital, Boston, MA) for 2 hr. The mem-
brane was washed with the TBST-20 solu-
tion and incubated for 1 hr with a 1:2000
dilution of a horseradish peroxidase–cou-
pled second antibody. The membrane was
washed with TBST-20 and then developed
using enhanced chemiluminescence (Pierce
Chemical Co., Rockford, IL). Relative
intensity of the bands was determined
using UnScanit software (Silk Scientific,
Inc., Orem, UT).
Immunohistochemistry
Paraffin sections 3 µm thin were prepared
and mounted on glass slides. The sections
were deparaffinized, rehydrated, and
permeabilized with hyaluronidase (1 mg/mL)
in a sodium acetate buffer. The sections
were placed in an antigen-retrieval solution
at 95°C for 45 min (Dako Corp.,
Carpenteria, CA) and nonspecific binding
was blocked with bovine serum albumin.
The sections were incubated with a 1:200
dilution of a KIM-1 primary antibody
(provided by J. Bonventre) or vimentin
antibody, washed with Tris-buffered saline
and exposed to a biotinylated second anti-
body for 1 hr. The sections were developed
using an avidin-biotin-peroxidase complex,
counterstained with H&E, and viewed
using a 60× oil objective. 
Results
Clinical Chemistry and Urinalysis
Cisplatin. A summary of the clinical chem-
istry data for all three nephrotoxicants is
presented in Table 1. The low dose
(0.3 and 1 mg/kg) of cisplatin produced
only minor changes in the histologic
appearance of the kidney or clinical chem-
istry at any time point during the experi-
ment. The high dose (5 mg/kg) of cisplatin
had minimal effect on urine or serum
chemistry relative to the values seen in the
time-matched control animals injected
with vehicle at 4, 24, and 48 hr (data not
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Table 1. Changes in serum and urine chemistry and organ and body weights 7 days after cisplatin and gentamicin treatment and 21 days after puromycin treatment.a
Cisplatin Serum Protein
dose Body weight Kwt Cr BUN Urine excretion
(mg/kg) (g) (g) (mg/dL) (mg/dL) Glucose/Cr Prot/Cr Ca/Cr (mg/day)
Vehicle 279 ± 7 2.5 ± 0.1 0.30 ± 0.01 15 ± 1 0.23 ± 0.01 1.0 ± 0.1 0.07 ± 0.01 39 ± 3
0.3 288 ± 8 2.7 ± 0.1 0.24 ± 0.02 14 ± 1 0.17 ± 0.06 1.1 ± 0.1 0.11 ± 0.02 28 ± 3
1 289 ± 10 2.7 ± 0.1 0.22 ± 0.04 11 ± 1 0.15 ± 0.04 1.5 ± 0.2 0.12 ± 0.03 39 ± 4
5 252 ± 3* 2.7 ± 0.3 1.4 ± 0.4* 63 ± 20* 6.1 ± 2.0* 1.8 ± 0.3* 0.23 ± 0.08* 66 ± 10
Gentamicin Serum Protein
dose Body weight Kwt Cr BUN Urine excretion
(mg/kg/day) (g) (g) (mg/dL) (mg/dL) Glucose/Cr Prot/Cr Ca/Cr (mg/day)
Vehicle 269 ± 7 2.0 ± 0.1 0.19 ± 0.02 16 ± 1 0.19 ± 0.02 0.5 ± 0.1 0.07 ± 0.01 5 ± 1
2 278 ± 8 2.1 ± 0.1 0.15 ± 0.02 13 ± 1 0.16 ± 0.02 0.4 ± 0.1 0.06 ± 0.01 4 ± 1
10 280 ± 6 2.1 ± 0.1 0.16 ± 0.03 13 ± 1 0.20 ± 0.02 0.5 ± 0.1 0.09 ± 0.02 5 ± 1
80 264 ± 7 2.2 ± 0.2 0.16 ± 0.03 15 ± 2 0.23 ± 0.02 1.3 ± 0.1* 0.14 ± 0.07* 14 ± 1*
240 252 ± 8 3.2 ± 0.2* 1.9 ± 0.1* 127 ± 41 0.49 ± 0.01* 4.9 ± 0.3* 0.26 ± 0.07* 142 ± 31*
Puromycin Protein
dose Body weight Kwt Serum Urine excretion
(mg/kg) (g) (g) Cr BUN Glucose/Cr Prot/Cr Ca/Cr (mg/day)
Vehicle 269 ± 7 2.0 ± 0.1 0.19 ± 0.02 16 ± 1 0.19 ± 0.02 0.5 ± 0.1 0.07 ± 0.01 91.7 ± 17
5 278 ± 8 2.1 ± 0.1 0.15 ± 0.02 13 ± 1 0.16 ± 0.02 0.4 ± 0.1 0.06 ± 0.01 99.5 ± 44
10 280 ± 6 2.1 ± 0.1 0.16 ± 0.03 13 ± 1 0.20 ± 0.02 0.5 ± 0.1 0.09 ± 0.02 1891 ± 1728
Abbreviations: Ca, calcium; Cr, creatinine; Kwt, total kidney weight in grams; Prot, protein.
aMean values ± 1 SE from ﬁve rats per group are presented. *p < 0.05 from control.
Table 2. Summary of observations indicative of cisplatin-, gentamicin-, and puromycin-induced renal 
dysfunction.a
Cisplatin Gentamicin Puromycin
Renal tubular dysfunction
Altered serum electrolyte/mineral concentration + + –/+
Calcuria + + +
Tubular injury
Proteinuria + + +
Single-cell necrosis + – –
Tubular degeneration + + –/+
Tubular regeneration + – –/+
Apoptosis – + –
Mononuclear/lymphocytic inﬁltrates + + +
Myelin ﬁgures (electron microscopy) NE + NE
Proximal tubular necrosis + + (high dose) +
Protein casts + + +
Focal segmental glomerulosclerosis – – +
Glomerular injury or other indicators of renal injury
Altered serum creatinine + + (high dose) –
Glomerular thickening of basement membrane + – +
Altered serum urea nitrogen + + (high dose) –
Abbreviations: NE, not evaluated; +, end point observed; –, end point not observed; –/+, end point observed in some
instances. 
aCisplatin (5 mg/kg), gentamicin (80 or 240 mg/kg/day), and puromycin (20 mg/kg/day). For cisplatin-treated rats, micro-
scopic alterations were evident at day 1. shown). However, 7 days after injection of
the 5 mg/kg dose of cisplatin, plasma crea-
tinine and serum BUN concentration were
elevated by approximately 5-fold. Rats
treated with the high dose of cisplatin
exhibited glucosuria (elevated glucose/crea-
tinine concentration ratio) indicative of
proximal tubular injury. They also exhib-
ited a 2-fold increase in urine protein and
calcium concentration. 
Gentamicin. Daily treatment of the rats
with 2 and 10 mg/kg doses of gentamicin
produced very little change in serum or
urine clinical chemistry compared with the
values seen in time-matched vehicle control
animals at day 7 (Table 1). Urinary total
protein was significantly increased (p <
0.001) in rats dosed at 80 mg/kg/day at
4 hr and at 7 days. They also exhibited an
increase in urinary Ca2+ concentration at 4
hr (p < 0.01) and 2, 3, and 7 days (p <
0.01) after administration of gentamicin
(data not shown). Because the degree of
renal injury was minimal in the strain of rat
SD-ICS (Charles River Labs) used in the
present studies, we repeated the study in
three additional rats using a higher dose of
gentamicin (240 mg/kg/day). This dose
produced the expected severe renal injury
as reﬂected by the marked increase in BUN
and creatinine. These rats also exhibited a
pronounced proteinuria and elevated levels
of glucose and Ca2+ in the urine (Table 1).
Puromycin.  Rats treated with
puromycin (20 mg/kg/day) for 21 days
exhibited marked proteinuria (Table 1) and
an elevation in urinary Ca2+. The chronic
loss of protein in the urine was reﬂected by
a dramatic fall in serum protein and albu-
min levels at day 21 in rats chronically
exposed to 20 mg/kg/day puromycin.
Despite the marked proteinuria, BUN and
creatinine were not signiﬁcantly elevated at
any of the time points in the study, indicat-
ing that the glomerular filtration rate
(GFR) remained relatively normal in
these rats.
Renal Histopathology
Cisplatin. The low dose (0.3 mg/kg) of cis-
platin had very little effect on the histology
of the kidney. Four of the five animals
treated with the 1 mg/kg dose of cisplatin
exhibited some degree of single-cell tubular
necrosis and some mild tubular degenera-
tion at 48 and 144 hr after administration
of the compound. Rats treated with the
high dose (5 mg/kg) of cisplatin exhibited
severe proximal tubular necrosis and the
formation of protein casts, especially in the
pars recta of proximal tubules (Table 2;
Figure 1A, B). There was also evidence of
mild interstitial inflammation and edema
in both the renal cortex and outer medulla,
and some glomeruli exhibited thickening of
the basement membrane. 
Gentamicin. Rats treated with gentam-
icin at 2 and 10 mg/kg/day exhibited no
discernable renal pathology. Even the rats
treated with the higher dose of gentamicin
(80 mg/kg/day) exhibited only subtle com-
pound-related changes in the histology of
the kidney after 3 and 7 days of exposure
(Table 2; Figure 1C, D). These changes
included minimal degeneration of some
proximal convoluted tubules, apoptosis,
tubular basophilia, tubular casts, increased
mitotic figures, and mononuclear cellular
infiltrates. Ultrastructural analysis revealed
that one control animal had essentially
normal proximal tubular epithelium,
whereas another had hyaline droplets of
different densities (Figure 1E). The proxi-
mal tubular epithelium of two treated ani-
mals exhibited large lysosomes of varying
density that accumulated lamellar material
forming typical myeloid bodies (Figure 1F).
In addition, all of the animals treated with
Mini-Monograph | Gene-based markers of renal toxicity
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Figure 1. Histopathological evidence of cisplatin- and gentamicin-induced proximal tubular toxicity.
Representative H&E-stained sections histological sections from kidney of (A) vehicle-treated (magniﬁca-
tion 20×), (B) cisplatin-treated rats (5 mg/kg, 6 days) (magniﬁcation 20×), (C) vehicle-treated rats (magniﬁ-
cation 200×), and (D) gentamicin-treated rats (80 mg/kg/day; 7 days) (magniﬁcation 200×). Representative
electron micrographs from (E) vehicle-treated rats (magniﬁcation 3,000×) and (F) gentamicin-treated rats
(80 mg/kg/day, day 7) (magniﬁcation 4,500×) . Increased apoptosis and cellular inﬁltrates and myelin ﬁg-
ures were observed in rats treated with gentamicin (80 mg/kg/day, day 7).240 mg/kg/day gentamicin for 7 days
exhibited severe proximal tubular necrosis
and formation of protein casts in the
proximal tubule.
Puromycin. There were minimal back-
ground ﬁndings in the control and treated
groups, defined as less than three foci of
the following: interstitial lymphocytic
inﬂammatory inﬁltrates, interstitial ﬁbrosis,
tubular mineralization, and tubular cysts in
the cortex or medulla. There was a dose-
related minimal increase in severity of one
or more of the following lesions: interstitial
lymphocytic cellular infiltrate, glomerular
sclerosis, lymphocytic perivascular cellular
infiltrate in the renal capsule, and tubular
regeneration in one of five animals from
each time point (Figure 2; Table 2). The
most significant findings were dilation of
renal tubules, protein casts, expansion of
the mesangial matrix material in the
glomerulus, and focal segmental glomeru-
losclerosis in the rats treated with
puromycin (20 mg/kg/day) for 21 days. In
two of ﬁve rats there were multiple areas of
involvement in the renal cortex, which
occupied approximately 25–35% of the
kidney. Sloughed tubular epithelial cells
were sometimes present in the tubular
lumen. However, the majority of the
glomeruli appeared normal at the light
microscopic level. 
Identiﬁcation of Tubular Toxicity
Based on Gene Expression Changes 
For each treatment (compound, dose, and
time), genes with statistically significant
expression changes were identiﬁed using the
approach described by Bushel et al. (2001).
Hierarchical clustering was used to aid in
visualization and biological interpretation of
this extensive data set, and in particular, to
identify correlated expression patterns that
reflect potential biological/toxicological
processes occurring in the renal tissues of
the animals treated with cisplatin, gentam-
icin, or puromycin at varying doses and
time points. Hierarchical clustering,
described by Eisen et al. (1998), was
applied across the various treatment groups,
doses, and time points, using a combined
list of genes identiﬁed to be altered statisti-
cally signiﬁcantly in at least one of the sam-
ples studied relative to control (Figure 3A,
B). Using this approach, it was possible to
extract correlated patterns and natural
classes present in the data set that could be
correlated with biological processes relevant
to nephron segment-speciﬁc toxicity as well
as gene expression alterations reflecting
histopathological changes.
Hierarchical clustering revealed two
distinct separations in experimental groups
that correlated with the severity of renal
toxicity. As shown in Figure 3A, the hierar-
chical order of the clustering tree indicated
several correlations and allowed sample
separation based on severity, region, and
type of toxicity. For instance, the hierarchi-
cal ordering of gene expression changes by
cisplatin (5 mg/kg/day, 24 and 144 hr),
gentamicin (2, 10, 80, and 240 mg/kg/day,
day 7), and puromycin (5 mg/kg/day, day
7; 20 mg/kg/day, days 1 and 7) fall within
one node and are much more closely corre-
lated compared with the remaining lower-
dose, earlier time point samples. This
separation in the expression patterns
appeared to be correlated with the severity
of the renal injury (based on changes in
serum biochemistry and/or urinalysis
changes or histopathology) and are linked
to the treatment, dose, time, and severity of
each of these compounds. The second
major node separating the remaining treat-
ment groups consists of samples associated
with less prominent renal toxicity. 
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Figure 2. Representative H&E-stained histological sections from kidney of (A, B) vehicle-treated and (C, D) puromycin-treated rats. (A, B) Intact renal tubules and
glomeruli and uniform nuclei are observed in controls. In addition, uniform tubules with single layer of epithelium lining are observed in renal cortex of control
rats. (C) Increased protein casts and necrosis of renal tubular cells observed in rats treated with puromycin (20 mg/kg/day, day 21). (D) Thickened glomerular
membranes and affected tubules observed in rats treated with puromycin (20 mg/kg/day, day 21). Magniﬁcation 40×.Mini-Monograph | Gene-based markers of renal toxicity
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Figure 3. Hierarchical clustering, as described
by Eisen et al. (1998), was applied across the
various treatment groups, doses, and time
points, using a combined list of genes identi-
fied to be altered statistically significantly in
at least one of the samples studied relative to
control. Gent, gentamicin. (A) Separation of
experimental groups. The A and B notation
behind the high-dose cisplatin indicates two
biological replicates. Gene expression
changes were determined using 2–4 replicate
hybridizations from pooled kidney samples
and include fluor-reversal. (B) Node contain-
ing several putative markers of renal toxicity.
Green indicates genes that are downregu-
lated; red indicates genes that are upregu-
lated in treated animals relative to control
animals. Accession numbers are from
GenBank (http://www.ncbi.nih.gov/GenBank/).
(C) PCA of cisplatin-induced (red), gentam-
icin-induced (green), and puromycin-induced
(yellow) gene expression changes at varying
doses and time points. The labels of severity
and region of toxicity were overlaid from the
clinical pathology data.
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Cisplatin 5 mg/kg 144 hr (A)Clustering based on gene expression
profiling of samples obtained from inde-
pendent replicate experiments performed
using the same compounds and protocols
can reveal if there are variations in gene
expression changes across studies. In Figure
3A, cisplatin 5 mg/kg, 144 hr (A) and cis-
platin 5 mg/kg, 144 hr (B) represent renal
gene expression changes observed based on
two independent experiments performed
with cisplatin in different groups of ani-
mals (A and B denote the ﬁrst and second
biological experiments, respectively). The
gene expression changes observed in these
two different experiments performed with
cisplatin at 5 mg/kg/day were highly corre-
lated, indicating minimal overall variability
in gene expression changes across two inde-
pendent in vivo experiments, and hence the
proﬁles clustered together. 
Multidimensional visualization by
PCA using all of the statistically altered
renal gene expression changes was used to
observe the spatial distribution of the
treatment groups in multidimensional
space (Figure 3C). This approach offers an
opportunity to visualize expression patterns
that can reflect similarities in biological
responses. The visualization of high-dimen-
sional data in two- or three-dimensional
principal components reveals unsupervised
clusters within the data. Samples can be
scored using the results of a PCA on known
samples, and these scores may place the
unknown into one of the previously identi-
ﬁed clusters where gene expression changes
are clearly linked to biological/pathological
events. As shown in Figure 3C, three major
separations of the various treatment groups
were evident. The first includes treatment
groups in which severe renal proximal
tubular toxicity was observed (cisplatin
5 mg/kg, 24 and 144 hr). The data from
these groups were clearly separated from
early time points after exposure to cisplatin
and from the low-dose samples where no
histologic evidence of tubular injury were
observed. In addition, the second principal
component shows separation of the high-
dose cisplatin data with tubular injury from
the puromycin data that exhibited marked
proteinuria and glomerular toxicity.
The samples analyzed by microarrays in
these experiments consisted of pooled sam-
ples. However, we further characterized the
response of individual animals at one
dose/time point for cisplatin (Thompson et
al. 2004) and for gentamicin (day 7) and
compared the response of these animals to
the animals from a related, biologically
replicated experiment. In the gentamicin
replicate experiment, the results from ani-
mals dosed with 240 mg/kg of gentamicin
for 7 days (to produce severe injury) were
compared with the results obtained using
the 80-mg/kg dose for 7 days in the initial
experiment. The higher dose (240 mg/kg)
resulted in the expected severe proximal
tubular necrosis and proteinuria. Although
not identical, the overall changes in renal
gene expression observed after treatment
with 240 mg/kg compared with 80 mg/kg
gentamicin for 7 days were still closely cor-
related and hence clustered together despite
the less severe changes in renal histology
and threshold changes in the urinary excre-
tion of protein, glucose, and Ca2+ observed
after treatment with 80 mg/kg gentamicin
(Figure 4). 
The power of microarray analysis is
that it allows elucidation of groups of genes
that correlate with certain expression pat-
terns that accompany particular types of
biological effects. Analysis of groups or
clusters of genes that contribute to similar
pathways/functions may be more robust
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Figure 4. Clustering of gentamicin-treated individual animals at 80 and 240 mg/kg after 7 days of exposure.
These two biological exposures were conducted independently, and the RNA from each experiment was
run on the same chip and analyzed using the same analytical approach. Green indicates genes that are
downregulated; red indicates genes that are upregulated in treated animals relative to control animals.
Accession numbers are from GenBank (http://www.ncbi.nih.gov/GenBank/). 
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AA874916
AA818502
AA955861
AA956164
AA899737
AA818118
AA818709
AA900947
AA874997
AA925982
AA955326
AA899769
AA899814
AA901183
AA858957
AA850744
AA819818
AA900860
AA899630
AA900992
AA956907
AA901095
AA899725
AA858477
AA818442
AA818152
AA819093
AA818640
AA899629
AA819424
AA818434
AA818247
AA955091
AA858746
AA900207
AA875070
AA859846
AA818795
AA899586
AA955185
AA900570
AA899558than focusing on a single gene. In addition,
gene clusters may be used to identify
known and novel putative gene-based
markers of renal toxicity and can poten-
tially direct future research to validate these
putative gene-based markers in urine/
serum using animal and clinical models.
Figure 5 shows a group of genes strongly
downregulated in samples that exhibited
proximal tubular necrosis. Many of these
genes are functionally localized to the prox-
imal tubules, further strengthening the
hypothesis that regional-specific toxicity
may be discerned through analysis of gene
expression patterns (Table 3). Interestingly,
the puromycin samples showed similar
downregulation of some of these genes,
indicating that tubular toxicity may have
occurred from this treatment. Indeed,
upon further histopathological evaluation,
the less prominent tubular toxicity was
observed in the rats receiving the higher
dose of puromycin for 21 days (Figure 4). 
Elucidation and Veriﬁcation 
of Putative Biomarkers 
One of the intended outcomes of these
studies was the elucidation of putative new
sensitive biomarkers of nephrotoxicity. We
examined the significantly changed genes
for those that displayed induction in a
dose- and time-dependent manner for fur-
ther verification in this study. Figure 6
shows a grouping of genes after high-dose
cisplatin and gentamicin treatment that
appear to be upregulated in a dose- and
time-dependent fashion. Overlap of these
genes on clusters derived from both the
NIEHS and Affymetrix microarrays indi-
cate several potential biomarkers of renal
toxicity/repair, including KIM-1, osteo-
pontin, vimentin, and several ESTs
(Figure 6). 
Multiple approaches were used to
robustly determine and conﬁrm the expres-
sion changes observed in the present
microarray studies. First, the genes that
were differentially modulated were deﬁned
using the approach of Chen et al. (1997)
that employs a specified confidence level
(95% in the present study) for determining
differentially expressed genes. Second, to
reduce false positives, replicate hybridiza-
tions (typically n = 4, with reverse labeling)
were performed using the pooled samples
and/or biological replicates, and a binomial
distribution was used to model the results
of the analyses at given confidence levels.
Third, dye reversal was used to avoid false
positives due to biases in Cy-dye–specific
Mini-Monograph | Gene-based markers of renal toxicity
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Figure 5. Evidence for puromycin-induced tubular toxicity based on gene expression proﬁling. A number of enzymatic and transporter functions that map to the
proximal tubular region of the kidney were shown to be downregulated in this cluster of genes. The strong downregulation of these genes in the puromycin-
exposed animals led to the hypothesis that puromycin also induced proximal tubular necrosis. Green indicates genes that are downregulated; red indicates
genes that are upregulated in treated animals relative to control animals. Accession numbers are from GenBank (http://www.ncbi.nih.gov/GenBank/). 
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AA925935 EST
AA899443 Rattus norvegicus CDK110mRNA
AA818361 EST
AA964628 Glucose-6-phosphatase
AA924904 EST
AI 137907 R. norvegicus alpha-1-macroglobulin mRNA, complete cds
AA900766 EST
AA997886 Rattus norvegicus cytochrome P458 2D18 mRNA, complete cds
AI 070884 Kidney androgen-regulated protein
AA924834 EST
AI 059765 ZAP 36/annexia IV
AA818636 Rat beta-galactoside-alpha 2.6-sialytransferase mRNA
AA998607 kvnurenine aminotransferase II
AI 385145 R. norvegicus mRNA for ras-related GTPase Rab29
AA866385 EST
AA818680 ornithine aminotransferase
AA925553 EST
AA901327 Epidermal growth factor
AA819745 Growth hormone receptor
AA818579 cystosolic cysteine dioxygenase 1
AA860013 ornithine decarboxylase
AA925145 EST
AA899969 EST
AA818440 beta-alanine-pyruvate aminotransferase
AA818741 EST
AA819087 EST
AA899732 EST
AA819309 Guanidinoacetate methyltransferase
AA818855 solute carrier family 15 (H+/peptide transporter), member 2
AI 059692 Eukarvotic elongation factor 2 kinase
AA957263 EST
AA858892 EST
AA998808 alanyl (membrane) aminopeptidase
AA819550 EST
AA955093 EST
AI 059021 Pancreatic lipase
AA92432 EST
AA925724 Transcription factor 2. Hepatic: LF-B3: variant hepatic nuclear factor
AA817972 Proteasome (prosome, macropain) 256S subunit, ATFase
AA900944 EST
AA925291 Nerve growth factor, gamma polypeptide
AA86601 EST
AA818463 EST
AA859075
AA819477 serum amyloid P-component
AA819101 ESTincorporation for speciﬁc genes, and genes
with highly variable expression changes
across hybridizations were flagged because
of a large coefﬁcient of variation or a modi-
fied z-score computation to detect outliers
(Bushel et al. 2001, 2002). Therefore,
examination of the data from these
repeated hybridizations yielded lists of
genes that were statistically validated as dif-
ferentially expressed. 
In addition, several of the observed
gene expression changes identified in the
present study were confirmed using alter-
nate approaches, including RT–PCR,
in situ hybridization, immunohistochem-
istry, and/or Western blot analysis. As
shown in Table 4, RT–PCR analysis was
performed using kidney RNA isolated from
rats treated with cisplatin for 24 hr or
144 hr or gentamicin exposed for 7 days.
Genes changed with microarray were gen-
erally in qualitative agreement when deter-
mined using RT–PCR. The expression of
genes known to be implicated in the
mechanism(s) of renal toxicity that were
confirmed include kallikrein, heme oxyge-
nase 1, clusterin, osteopontin, and KIM-1
(Table 4; Figure 7A). In addition, several
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Table 3. Downregulated gene expression changes correlated with regional speciﬁc damage.a
Renal distribution and enzyme Distributionb Cisplatin Gentamicin
Glomerulus
Adenosine-deaminasec
Proximal tubule
Glucose-6-phosphatased S1 > S2 > S3 √
Fructose-1,6-bisphosphatased S1 < S2 > S3
Phosphoenolpyruvate carboxylkinased S1 > S2 > S3
Fructokinased S1 = S2 < S3
Fructose-1 phosphate aldolased S1 = S2 > S3
Glycerokinased S1 = S2 > S3
Glycerol 3-phosphate dehydrogenased S1 = S2 = S3
Glutamine synthetase S3 √√
Alanine aminotransferase S1 = S2 < S3 √
Ornithine aminotransferase S1 = S2 < S3
Gamma glutamyltranspeptidasee S1 < S2 < S3
Gamma glutamyl cysteine synthetase S3
Gluthathione S-transferasee S1 = S2 = S3 √√
Cytochrome P450e S1 = S2 = S3 √√ √
L-Hydroxyacid oxidasee S1 = S2 < S3 √
Peroxisomes (D-amino acid oxidase/catalase)e S1 = S2 < S3 √
Aminopeptidasesf S1 < S2 < S3 √
Alkaline phosphatase S1 = S2 = S3
Fatty acyl-CoA oxidase S1 = S2 < S3
Choline oxidase S1 < S2 = S3
25(OH)-D3-1α-hydroxylaseg S1 = S2 < S3 √
Vitamin D binding proteing √
Solute carrier family 15 (H+/peptide) √
Isocitrate dehydrogenase 1 √
Abbreviations: √, change in gene expression observed; √√, change in gene expression observed in more than 1 gene in
this family. aInformation modiﬁed from WHO (1991). bS1, S2, and S3 denote renal tubular subregions. cPurine metabolism
related. dSugar metabolism related. eRole in xenobiotic metabolism. fPeptide/amino acid metabolism. gVitamin D related. 
Figure 6. Putative gene-based markers of nephrotoxicity. Graph represents level of change relevant to control animals The level of expression is shown as the
log2 of the ratio of the expression in treated samples versus vehicle-treated samples. The values for the expression in cisplatin-treated animals is shown in
closed bars, and the open bars represent the expression in gentamicin-exposed animals.
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Table 4. Comparison of cDNA microarray and RT–PCR measurements. 
Cisplatina Gentamicin
GenBank  RT–PCR cDNA microarray Day 2 RT–PCR Day 7 RT–PCR
accession no.b Gene (5 mg/kg) (5 mg/kg) (10 mg/kg/day) (80 mg/kg/day) (10 mg/kg/day) (80 mg/kg/day)
AA964431 Osteopontin 5.2 4.1 0.9 1.1 1.4 3.9
AA901117 Inositol polyphosphate kinase 0.5 0.7 – – – –
AA920287 L-Arginine-glycine amidinotransferase 0.3 0.5 – – – –
AA858514 Prosaposin 1.07 1.05 1.0 1.0 0.9 0.9
AI058493 Synaptogyrin 2 0.5 1.8 – – – –
AA957270 EST 3.5 2.9 – – – –
M19647 Kallikrein – – 1.01 1.0 0.5 0.3
AA946503 Lipocalin 2 7.7 –c –– ––
–, not done or not on platform. aAll cisplatin values are from 144-hr time point except L-arginine glycine amidinotransferase, which is from the 24-hr time point. bFrom GenBank
(http://www.ncbi.nih.gov/GenBank/). cSequence not present on cDNA microarray. Observed based on similarity to KIM-1 expression on Affymetrix platform (data not shown).genes for which there is limited under-
standing of a role in renal toxicity were
validated. These include inositol polyphos-
phate multikinase and L-arginine-glycine
amidinotransferase. In addition to
RT–PCR veriﬁcation, heme oxygenase and
KIM-1 protein expression in rat kidney
after cisplatin treatment was confirmed by
Western blot analysis (Figure 7A–D).
Using in situ hybridization, expression of
KIM-1 was confirmed to be increased in
the proximal tubule after exposure to cis-
platin (Figure 8B). Increased vimentin
expression was also conﬁrmed by immuno-
histochemistry (Figure 8D).
RT–PCR verification of two ESTs
identiﬁed to be induced in rat kidney after
exposure to 5 mg/kg cisplatin for 144 hr
was also performed. Lipocalin 2 (LCN2)
(GenBank accession no. AA946503)
expression was initially identified in cis-
platin gene expression data generated with
the same RNA on an Affymetrix platform
(data not shown). In fact, the expression of
LCN2 was similar to that observed for
KIM-1. Induction of KIM-1 expression
after cisplatin treatment was confirmed by
in situ hybridization, RT–PCR, and
Western blot analysis (Figure 7). The
increased expression of another EST
(GenBank accession no. AA957270; now
known as a tumor necrosis factor (TNF)
receptor superfamily, member 12a, or
Tweak receptor) was verified using
RT–PCR (Table 4). The role of Tweak
receptor in mediating cisplatin renal toxic-
ity remains to be determined. 
Discussion
In this study, we used cDNA microarrays
to examine temporal changes in gene
expression patterns in the kidney after
treatment of rats with cisplatin, gentam-
icin, and puromycin, three nephrotoxicants
that primarily injure the proximal tubule
(cisplatin and gentamicin) or the glomeru-
lus (puromycin) via different mechanisms
of action. The results of our microarray
study are consistent with numerous reports
of the modulation in expression of various
mRNA after renal injury induced by cis-
platin, gentamicin, or puromycin (Girton
et al. 2002; Huang et al. 2001). For instance,
using data from cisplatin treatment, it was
possible for us to functionally annotate gene
expression changes to various previously
published and novel categories. These cate-
gories include biochemical pathways related
to creatinine biosynthesis, osmoregulation,
kinase signaling, cell cycle–related genes,
renal transporters, renal injury, and regener-
ative responses, as well as gene expression
changes related to drug metabolism, detoxi-
ﬁcation, and drug resistance.
For example, we detected a reduction in
the expression of L-arginine-glycine
amidinotransferase and guanidinoacetate
methyltransferase at days 1 and 6, respec-
tively, after treatment with 5 mg/kg cis-
platin, a dose that induced renal lesions.
Mapping of these gene products to a bio-
chemical pathway points to a role for them
in the formation of creatinine from L-argi-
nine (see map in Kramer et al. 2004).
Creatinine is formed from creatine and
excreted by the kidneys. Traditionally, mea-
surements of increased serum urea and crea-
tinine are used clinically as indices of
changes in glomerular filtration rate.
However, they are relatively insensitive
markers of glomerular injury, as typically
up to 75% of nephrons have to be non-
functional before there are signiﬁcant eleva-
tions in serum levels of BUN or creatinine.
Although ours is the ﬁrst study to demon-
strate the modulation in the expression of
these genes in rat kidney after cisplatin
treatment, Lee et al. (1998) demonstrated
that cisplatin alters the expression of L-argi-
nine-glycine amidinotransferase and guani-
dinoacetate methyltransferase in the male
rat reproductive tract. Using Western blot
analysis, Lee et al. (1998) demonstrated
that L-arginine-glycine amidinotransferase is
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Figure 7. (A) Western blot confirms KIM-1 expression in rat kidney after cisplatin treatment (144 hr,
5 mg/kg) in vehicle control and cisplatin-treated animals. n = 5. (B) RT–PCR of KIM-1 mRNA, cyclophilin B
(cyclo, cytb1, and GAPDH were used as controls). (C) Western blot of heme oxygenase. (D) Quantitation
of heme oxygenase mRNA shows that increased mRNA expression at 4 hr precedes peak of protein
expression (24 hr).
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Figure 8. In situ hybridization conﬁrms KIM-1 expression is very low in a kidney from a control animal (A)
and highly induced in a cisplatin-exposed kidney (B). Immunohistochemistry shows basal expression of
vimentin expression in the kidney of a control rat (C) and induction in an animal treated with cisplatin (D).also expressed in the rat kidney and
guanidoacetate methyltransferase mRNA is
expressed in the kidneys, testes, and epi-
didymis of rats. More recently Yasuda et al.
(2000) demonstrated decreases in urinary
concentrations of guanidinoacetic acid, cre-
atinine, and creatine after cisplatin treat-
ment. These studies also suggested that
production of guanidinoacetic acid, a pre-
cursor of creatinine that is affected by meta-
bolic disturbance when kidney function is
damaged, may be a marker of renal damage.
Our studies revealed that there was a
marked decrease in the expression of
L-arginine-glycine amidinotransferase in the
kidney as early as day 1 after cisplatin treat-
ment. The biochemical outcome expected
from inhibition of L-arginine-glycine
amidinotransferase would be a decrease in
the formation of guanidoacetic acid. It is
possible that this renal molecular response,
in part, may precede or may correlate with
the decrease in urinary excretion of
guanidoacetic acid reported by Yasuda et al.
(2000). Decreased renal expression of L-
arginine-glycine amidinotransferase in rats
treated with 1 mg/kg, a dose of cisplatin
that resulted in mild pathological changes,
was evident at day 6 but not at day 1, pre-
sumably reﬂecting a later onset of toxicity.
In contrast, treatment with 5 mg/kg cis-
platin decreased the expression of L-argi-
nine-glycine amidino transferase expression
at day 1, and downregulation of guanidi-
noacetate methyltransferase was most
prominent after 6 days. The temporal dif-
ferences in the modulation of two genes in
the same biochemical pathway is unclear;
however, it may be indicative of progression
of toxicity and biochemical feedback mech-
anisms to compensate for altered creatinine
clearance. L-arginine-glycine amidinotrans-
ferase was also downregulated in renal tissue
of rats treated with gentamicin and puro-
mycin, further implicating the potential
importance of this pathway in overall
response to renal toxicity. Altered expres-
sion of these genes is likely to reflect an
altered protein product (not determined in
the present studies). This suggests that inhi-
bition of these enzymes may lead to an
increase in levels of arginine, an immediate
substrate for nitric oxide synthase (NOS),
producing a nitric oxide (NO) precursor
that can lead to the formation of NO. A
role for NO has been implicated in models
of renal injury (Srivastava et al. 1996), and
L-arginine has been demonstrated to be
both protective (Andoh et al. 1997) and
harmful (Tome et al. 1999) in models of
renal injury. The authors speculate that
although the initial effects of NO formation
after renal injury may be beneﬁcial, the pro-
longed inhibition of the L-arginine pathway
may contribute to renal damage because of
excessive buildup of NO, which has been
implicated in numerous renal pathologies
(Valdivielso and Blantz 2002). NO is an
important regulator of renal vascular tone
and can modulate renal blood flow,
glomerular hemodynamics, and the contrac-
tility of mesangial cells. In addition, NOS is
present in the renal tubular segments and
the juxtaglomerular apparatus and may
enhance the renal damage incurred after
nephrotoxicant administration. 
The expression of kallikrein decreased in
the kidney after gentamicin (80 mg/kg/day,
7 days) (Table 4). Kallikrein is a serine pro-
tease that cleaves kininogen to produce
kinin, a vasoactive and natriuretic peptide
(Clements 1989; Schmaier 2003). Kallikrein
is produced and secreted in distal nephron
segments and has been implicated in the
control of sodium and water excretion and
the long-term control of arterial pressure.
More recently, kallikrein has also been
implicated in determining the pathogenesis
of renal injury after administration of
nephrotoxicants. For example, Murakami
et al. (1998) reported that systemic transfec-
tion of the kidney with an adenovirus
expressing kallikrein attenuates the develop-
ment of gentamicin-induced nephrotoxicity
in rats. Murakami et al. (1998) suggest that
the renoprotective effect of kallikrein gene
delivery may be related to the ability of
kinins to activate phospholipase A and pre-
vent phospholipidosis, which is characteris-
tic of gentamicin toxicity. In addition,
recent studies have revealed that urinary
kallikrein levels are reduced and there are
polymorphisms in the kallikrein gene in
patients with renal disease (Yu et al. 2000,
2002). These results suggest the potential
utility of gene expression proﬁling to iden-
tify genes and pathways that may play a role
in determining the genetic susceptibility to
nephrotoxicity (toxicogenomics). 
Puromycin treatment, in the present
studies, was associated primarily with
glomerular toxicity, in addition to the less
prominent proximal tubular toxicity.
Numerous genes were identiﬁed as upregu-
lated or downregulated at various doses and
time points after puromycin treatment.
Examples of genes upregulated primarily at
24 hr after treatment with 5 mg/kg puro-
mycin include serum amyloid p-component
(GenBank accession no. AA819447) and
dentin sialophosphoprotein (GenBank
accession no. AA899472; discussed below),
dihydropyrimidinase (GenBank accession
no. AI111911), cathepsin H (GenBank
accession no. AA819336), cathepsin B
(GenBank accession no. AA963225), alco-
hol dehydrogenase (GenBank accession no.
AA875140), solute carrier) family 4,
member 4 (SLC4A4; GenBank accession
no. AI144995), macrophage inflammatory
protein 1-alpha (Mip-1-alpha; GenBank
accession no. AA924105), interferon, alpha
inducible protein 27-like (GenBank acces-
sion no. AA955996), retinol binding pro-
tein (GenBank accession no. AA860061),
and glucose-6-phosphatase (GenBank acces-
sion no. AA964628). An increase in expres-
sion of transporter genes may function to
facilitate reuptake of solutes and small mole-
cules passing through the damaged glomeru-
lus. Solute carrier family 4, for example, is
involved in the coupled movement of
sodium and bicarbonate; the expression of
this gene may be among the renal responses
for maintaining solute homeostasis during
renal injury. Cathepsins are primarily cys-
teine-dependent lysosomal proteases and
play an important role in protein degrada-
tion and turnover. The authors speculate
that the upregulation of cathepsin genes
may be a compensatory response to allow
for protein degradation as the nephron com-
pensates for proteinuria by increasing pro-
tein reuptake associated with glomerular
toxicity. In addition to the genes described
above, retinol-binding protein was upregu-
lated in the present study and retinol-bind-
ing protein mRNA is known to be expressed
in rat proximal tubules (Makover et al.
1989). It is likely that the induction of
retinol-binding protein may be in response
to increased urinary loss associated with
glomerular and/or tubular toxicity. Recent
studies demonstrate that urinary retinol-
binding protein has been investigated as a
prognostic marker of proximal tubular dys-
function in patients with glomerulopathies
(Kirsztajn et al. 2002). 
In contrast to the observed upregulation
of dentin sialophosphoprotein at 24 hr after
treatment with 5 mg/kg/day puromycin,
dentin sialophosphoprotein was among some
of the more downregulated genes at 24 hr
after treatment with 20 mg/kg puromycin.
Acidic nuclear phosphoprotein 32 (GenBank
accession no. AI070967), L-glycine arginine
amidinotransferase (GenBank accession no.
AA900287, discussed earlier), and cytosolic
epoxide hydrolase (GenBank accession no.
AA819830) were downregulated at 24 hr
after treatment with 20 mg/kg puromycin.
Although the role of these genes in the mol-
ecular responses to glomerular toxicity is
unclear, the downregulation of some of
these genes (i.e., cytosolic epoxide hydrolase,
acidic nuclear phosphoprotein 32) was
observed at both 24 hr and after 7 days of
treatment with 20 mg/kg/day of puromycin.
Hydrolases have been identified in rat
glomerular mesangial cells and have been
implicated in glomerulonephritis (Nakao
et al. 1999). 
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tamicin, and puromycin generally occur in
discrete anatomical regions (e.g., tubular or
glomerular components), although as
observed in this study, injury can diffuse to
additional regions of the nephron when
toxicity is severe. Discrete toxicity to an
organ with site-selective functional capacity
suggests that observed changes of the bio-
chemical properties of the affected renal
region can provide pertinent information
regarding the molecular outcome of the
lesion. To take advantage of this in facili-
tating the interpretation of mRNA expres-
sion changes in our study, we used the
published literature related to enzymology
of kidney tissue to compile information
regarding the expression of specific genes
within speciﬁc regions of the nephron, par-
ticularly within various tubular segments
(Table 3) (Mattenheimmer 1968; WHO
1991). As shown in Figure 4, decreased
expression of several mRNAs was detected
by microarray proﬁling, particularly in kid-
neys of rats treated with cisplatin (5 mg/kg,
day 6) and to a lesser extent after gentam-
icin treatment (80 mg/kg/day, day 7). One
explanation could be that the loss of expres-
sion of these RNAs could, in part, reflect
massive injury and death of proximal tubu-
lar cells. Although necrosis of tubular seg-
ments was confirmed histologically after
treatment with each of the three com-
pounds, it varied in severity (cisplatin >
gentamicin > puromycin). One important
point to highlight is that the large grouping
of genes that are downregulated and
grouped together in the clustering diagram
(Figure 5) could, as a group, serve as a sen-
sitive diagnostic indicator of proximal tubu-
lar damage. We conﬁrmed this by using this
set of genes to correctly predict puromycin-
induced proximal tubular injury before
histopathological analysis was conducted.
Further work will be needed to validate the
regulation of the expression of these genes
during regenerative/repair processes.
This work further highlights the appli-
cation of microarray in identifying putative
biomarkers of injury. For practical consider-
ations in detection assays, it may be most
useful to consider those genes that have low
expression in control tissue but are induced/
upregulated with damage. In this article we
have identiﬁed several potential biomarkers
that appear to be upregulated in a dose- and
time-dependent manner upon injury. These
include KIM-1, osteopontin, clusterin, and
several ESTs, including two that were
recently deﬁned, LCN2 and TNF receptor
superfamily, member 12a (Tweak receptor).
Although our study confirmed that the
expression levels of these genes did increase
in the kidney, further work will be needed
to truly validate these as biomarkers of
nephrotoxicity. Studies to investigate
reversibility, speciﬁcity, and sensitivity will
be needed as part of this validation (Kramer
et al. 2004). One of these gene products,
KIM-1, is a membrane-spanning protein
cleaved on the extracellular surface after
tubular injury (Bailly et al. 2002). In addi-
tion, antibodies to KIM-1 are now being
used to measure protein levels in human
urine after renal ischemic injury (Han et al.
2002). This study indicates that KIM-1
may indeed be a speciﬁc marker of tubular
injury, which could provide a more sensi-
tive indication of damage compared with
traditional clinical measurements (Han
et al. 2002). As mentioned earlier, RT–PCR
veriﬁcation of two ESTs induced after expo-
sure to 5 mg/kg cisplatin for 144 hr was per-
formed. Tweak receptor, or TNF receptor
superfamily, member 12 (GenBank acces-
sion no. AA957270), belongs to the TNF
receptor superfamily. Death ligands and
receptors such as TNF participate in apop-
tosis regulation in the course of renal injury
(Ortiz et al. 2001), and its induction is likely
involved in apoptotic signaling and regula-
tory mechanisms contributing to cisplatin-
induced renal injury. LCN2 (GenBank
accession no. AA946503) was identiﬁed as a
putative biomarker of kidney injury based
on the similarity of its expression pattern
to KIM-1. 
The human homolog of LCN2 is
neutrophil-associated lipocalin (NGAL)
and the mouse homolog is 24P3. LCN2
has been implicated in the regulation of
cell homeostasis and immune response and
can function as a carrier protein for the
general clearance of endogenous and exoge-
nous compounds (Flower 1996; Flower et
al. 2000; Yang et al. 2003). Lipocalin prod-
ucts have been found in neutrophilic gran-
ules and may play a role in apoptosis
(Devireddy et al. 2001; Yang et al. 2003).
NGAL/24p3 expression has also been
detected in inflamed epithelia (Nielsen
et al. 1996), perhaps explaining that the
appearance of this transcript may be related
to the damage occurring in the renal
tubules and the accompanying infiltrates
observed histopathologically. Relevant to
the present studies is the role implicated for
lipocalin superfamily members (i.e.,
NGAL/24p3) in inducing the formation of
kidney epithelia (Yang et al. 2003).
However, the underlying molecular signal-
ing mechanism(s) are not fully known.
NGAL protein has been identified as a
complex with matrix metalloproteinases in
urine of patients with cancer (Yan et al.
2001). Lipocalin-type prostaglandin D syn-
thase (also known as L-PGDS or β-trace) is
another member of the lipocalin family
(Hoffmann et al. 1993; Nagata et al. 1991),
and elevated serum and urinary levels of
β-trace (L-PGDS) have been observed in
patients with renal failure (Hoffmann et al.
1997; Melegos et al. 1999). L-PGDS is a
secretory glycoprotein that catalyzes the iso-
merization of a precursor of prostanoids,
prostaglandin (PG) H2, to produce
prostaglandin D-2 (Urade and Hayaishi
2000). Oda et al. (2002) developed and
evaluated an enzyme-linked immunosorbent
assay (ELISA) method to screen for human
urinary L-PGDS. Using this method, Oda
et al. determined that L-PGDS excretion
was signiﬁcantly increased in patients with
renal disease, even in the absence of
increases in serum creatinine. Therefore, its
ability to be monitored in urine of patients
(Yan et al. 2001) and, in particular, the abil-
ity to monitor L-PGDS (a member of the
lipocalin family) in urine of patients with
epithelial renal disease warrants its further
evaluation in models of renal injury. This
premise is confirmed in these studies. In
addition to the ESTs described above, the
expression of several other ESTs (e.g.,
GenBank accession nos. AA819209,
AA899472, and AA899737) were com-
monly modulated by cisplatin and gentam-
icin at doses that caused proximal tubular
toxicity. In most instances, the expression of
these ESTs correlated with severity of proxi-
mal tubular injury, and hence, expression
was more robust in cisplatin-treated com-
pared with gentamicin-treated rats with
tubular toxicity. For instance, one of the
ESTs (GenBank accession no. AA899472)
appears to have weak similarity to dentin
phosphoprotein precursor/dentin sialopro-
tein (DSP), whose role in response to renal
tubular injury has not been previously stud-
ied. DSP is a 53-kDa protein that has an
overall composition similar to that of the
sialoprotein osteopontin (Ritchie et al.
1994). An increase in level of osteopontin
mRNA expression in the present studies was
observed with cisplatin and gentamicin
treatment (Figure 3B) [for RT–PCR valida-
tion data, refer to Thompson et al. (2004)].
Although little is known about the func-
tion/role of DSP in response to renal injury,
an increase in the expression of osteopontin
in proximal tubular epithelium has been
demonstrated in human and animal models
of renal injury and can be associated with
monocyte or macrophage infiltration
(Hudkins et al. 2001; Magil et al. 1997;
Pichler et al. 1995). Khan et al. (2002)
reported concomitant renal expression and
urinary excretion of osteopontin in a rat
model of ethylene glycol–induced calcium
oxalate nephrolithiasis. Expression of osteo-
pontin protein and mRNA in proximal
tubular epithelium has been reported in
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inﬂux in both pretransplant donor biopsies
and biopsies with cyclosporine toxicity
(Hudkins et al. 1999, 2001). 
Induction of clusterin expression in
these studies was observed after cisplatin-
and gentamicin-induced renal injury and
has great potential to be used as a bio-
marker of nephrotoxicity. Clusterin is a
secreted heterodimeric glycoprotein that
circulates in blood at concentrations of
50–300 µg/mL (Rosenberg and Silkensen
1995a, 1995b). Clusterin has been induced
in a variety of models of renal tubular
injury and/or remodeling after treatment
with cisplatin (Huang et al. 2001;
Silkensen et al. 1997) as well as in tubular
epithelial cells, in response to proteinuria,
in kidneys of nephrotic rats (Correa-Rotter
et al. 1998) after puromycin treatment.
Depletion of clusterin enhances immune
glomerular injury in the isolated perfused
kidney (Saunders et al. 1994), and mice
deficient in clusterin are more susceptible
to injury due to immunocomplexes
(Rosenberg et al. 2002). Urinary and
serum clusterin levels have been studied in
various models of renal injury (Aulitzky
et al. 1992) and may play a role in early
detection of renal injury. Clearly, the
potential use of clusterin as a biomarker of
nephrotoxicity has to be conﬁrmed. 
Numerous efforts are ongoing to iden-
tify and validate markers of renal function
and injury in rodent and human models.
Muramatsu et al. (2002) demonstrated that
cysteine-rich protein 61, a secreted growth
factor–inducible immediate early gene, is
induced in proximal straight tubules of
rodents within 2 hr of renal ischemia and
can be detected in rat urine as early as
3–6 hr after renal injury. Cystatin C is a
13-kDa plasma protein that inhibits cys-
teine proteases and is freely filtered at the
glomerulus. Cystatin C appears to have
improved diagnostic accuracy compared
with creatinine measurements as a serum
marker of GFR (Christensson et al. 2003;
Laterza et al. 2002; Newman 2002). Oda
et al. (2002) have demonstrated the utility
of monitoring lipocalin-type urinary
β-trace in patients with renal disease. Star
et al. (2002) noted that the approach
described in the article by Oda et al.
(2002) for developing and evaluating an
ELISA-based approach for lipocalin-type
urinary β-trace provides valuable insight
into efforts that need to be undertaken to
translate a novel marker into a valuable
-laboratory assay. 
In conclusion, this study indicates that
gene expression arrays may be used to dis-
cern regional specific damage of nephro-
toxicity. Additionally, this study provides a
foundation for opportunities that exist to
apply gene expression profiling to begin
identifying novel markers of renal toxicity.
Further expansion of these analyses may
lead to the identiﬁcation of groups of genes
that could ultimately result in the detection
of sensitive markers of renal damage.
Traditional measures of renal damage, such
as proteinuria, creatinine clearance,
and elevated BUN, usually occur after sig-
nificant kidney damage has occurred.
Elucidation and validation of new sensitive
markers could help clinicians more effi-
ciently monitor patients who are adminis-
tered potentially nephrotoxic drugs. 
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